Next Article in Journal
Analysis of the Advisability of Using Solar Collectors in a Single-Family House in Poland and Spain
Previous Article in Journal
A Cross-Reactive Mouse Monoclonal Antibody against Rhinovirus Mediates Phagocytosis In Vitro
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

A Moonlighting microRNA: Mechanism(s) of miR-122-Mediated Viral RNA Accumulation †

1
Department of Microbiology & Immunology, McGill University, Montreal, QC H3G 1Y6, Canada
2
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
3
Center for Genomics and Systems Biology, Department of Biology, New York University, New York, NY 10003, USA
4
Division of Biology, New York University, Abu Dhabi, UAE
5
Department of Biochemistry, McGill University, Montreal, QC H3G 1Y6, Canada
*
Author to whom correspondence should be addressed.
Presented at Viruses 2020—Novel Concepts in Virology, Barcelona, Spain, 5–7 February 2020.
Proceedings 2020, 50(1), 131; https://doi.org/10.3390/proceedings2020050131
Published: 15 July 2020
(This article belongs to the Proceedings of Viruses 2020—Novel Concepts in Virology)

Abstract

:
Hepatitis C virus (HCV) is a positive-sense RNA virus that interacts with a human-liver-specific microRNA, termed miR-122. miR-122 binds to two sites in the 5′ untranslated region (UTR) of the viral genome, and this interaction promotes HCV RNA accumulation. This interaction is important for viral RNA accumulation in cell culture, and miR-122 inhibitors have been demonstrated to be efficacious in reducing HCV titers in chronic HCV-infected patients. However, the precise mechanism(s) of miR-122-mediated viral RNA accumulation have remained elusive. We have used biophysical analysis and assays for viral replication in cell culture to understand the interactions between the human Argonaute 2 (hAgo2):miR-122 complex and the HCV genome. In addition, we have analyzed several resistance-associated variants which were isolated from patients who underwent miR-122 inhibitor-based therapy in order to shed light on novel mechanisms of antiviral resistance. Our results provide a new model for miR-122:HCV RNA interactions and demonstrate that miR-122 plays at least three roles in the HCV life cycle: (1) miR-122 acts as an RNA chaperone to suppress an energetically favorable secondary structure and allows the viral internal ribosomal entry site (IRES) to form; (2) miR-122 binding to the 5′ terminus protects the genome from the activity of cellular pyrophosphatases (DOM3Z and DUSP11) and subsequent exonuclease-mediated decay; and (3) the Argonaute (Ago) protein at Site 2 makes direct contact with the HCV IRES, enhancing viral translation. In addition, analyses of several resistance-associated variants that were isolated from patients that underwent miR-122 inhibitor-based therapy suggests that mutations in the 5′ terminus alter the structure of the 5′ UTR in a manner that promotes RNA chaperone activity or viral genome stability, even in the absence of miR-122. Taken together, these findings provide insight into the mechanism(s) of miR-122-mediated viral RNA accumulation and suggest new mechanisms of antiviral resistance which are mediated by changes in RNA structure.

Share and Cite

MDPI and ACS Style

Chahal, J.; Gebert, L.F.; Gan, H.H.; Gunsalus, K.C.; MacRae, I.J.; Sagan, S.M. A Moonlighting microRNA: Mechanism(s) of miR-122-Mediated Viral RNA Accumulation. Proceedings 2020, 50, 131. https://doi.org/10.3390/proceedings2020050131

AMA Style

Chahal J, Gebert LF, Gan HH, Gunsalus KC, MacRae IJ, Sagan SM. A Moonlighting microRNA: Mechanism(s) of miR-122-Mediated Viral RNA Accumulation. Proceedings. 2020; 50(1):131. https://doi.org/10.3390/proceedings2020050131

Chicago/Turabian Style

Chahal, Jasmin, Luca FR Gebert, Hin Hark Gan, Kristin C Gunsalus, Ian J MacRae, and Selena M Sagan. 2020. "A Moonlighting microRNA: Mechanism(s) of miR-122-Mediated Viral RNA Accumulation" Proceedings 50, no. 1: 131. https://doi.org/10.3390/proceedings2020050131

Article Metrics

Back to TopTop